T. Legigan

发表

Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.

T. Legigan, J. Clarhaut, B. Renoux, 2013, European journal of medicinal chemistry.

β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update.

T. Legigan, J. Clarhaut, B. Renoux, 2014, European journal of medicinal chemistry.

A new cyclopamine glucuronide prodrug with improved kinetics of drug release.

J. Muller, T. Legigan, B. Renoux, 2011, Organic & biomolecular chemistry.

Surface functionalization by covalent immobilization of an innovative carvacrol derivative to avoid fungal biofilm formation

V. Humblot, T. Legigan, S. Papot, 2015, AMB Express.

Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc00472a Click here for additional data file.

P. Poinot, A. le Pape, S. Lerondel, 2017, Chemical science.

Evaluation of Cytotoxic Properties of a Cyclopamine Glucuronide Prodrug in Rat Glioblastoma Cells and Tumors

A. Gaillard, J. Muller, T. Legigan, 2014, Journal of Molecular Neuroscience.

Multivalency To Inhibit and Discriminate Hexosaminidases.

D. Vocadlo, J. Désiré, T. Legigan, 2017, Chemistry.

The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.

A. le Pape, S. Lerondel, T. Legigan, 2012, Angewandte Chemie.

An enzyme-responsive system programmed for the double release of bioactive molecules through an intracellular chemical amplification process.

F. Guilhot, T. Legigan, J. Clarhaut, 2013, Organic & biomolecular chemistry.

Synthetic deoxynojirimycin derivatives bearing a thiolated, fluorinated or unsaturated N-alkyl chain: identification of potent α-glucosidase and trehalase inhibitors as well as F508del-CFTR correctors.

J. Désiré, J. Bertrand, T. Legigan, 2015, Organic & biomolecular chemistry.

Design and synthesis of α-carboxy nucleoside phosphonate analogues and evaluation as HIV-1 reverse transcriptase-targeting agents.

A. Maguire, J. Balzarini, T. Legigan, 2015, The Journal of organic chemistry.

One-Pot Synthesis of Phosphinylphosphonate Derivatives and Their Anti-Tumor Evaluations

T. Legigan, M. Monteil, M. Lecouvey, 2021, Molecules.

Active Esters as Pseudostoppers for Slippage Synthesis of [2]Pseudorotaxane Building Blocks: A Straightforward Route to Multi-Interlocked Molecular Machines.

T. Legigan, F. Coutrot, B. Riss‐Yaw, 2016, Chemistry.

A mechanically interlocked molecular system programmed for the delivery of an anticancer drug.

P. Poinot, D. Leigh, V. Aucagne, 2015, Chemical science.

β‐Glucuronidase‐Responsive Prodrugs for Selective Cancer Chemotherapy: An Update

T. Legigan, J. Clarhaut, B. Renoux, 2014 .

Synthesis and preliminary anticancer evaluation of new triazole bisphosphonate-based isoprenoid biosynthesis inhibitors.

T. Legigan, F. Barbault, M. Monteil, 2021, European journal of medicinal chemistry.

Evaluation of Cytotoxic Properties of a Cyclopamine Glucuronide Prodrug in Rat Glioblastoma Cells and Tumors

A. Gaillard, J. Muller, T. Legigan, 2014, Journal of Molecular Neuroscience.

Selective Release of a Cyclopamine Glucuronide Prodrug toward Stem-like Cancer Cell Inhibition in Glioblastoma

U. Cortes, R. Bensadoun, T. Legigan, 2014, Molecular Cancer Therapeutics.

A convenient synthetic route towards H-bisphosphinates.

T. Legigan, M. Monteil, M. Lecouvey, 2018, Organic & biomolecular chemistry.

Formation of 1-Hydroxymethylene-1,1-Bisphosphinates through the Addition of a Silylated Phosphonite on various Trivalent Derivatives.

T. Legigan, M. Monteil, M. Lecouvey, 2020, The Journal of organic chemistry.

Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.

F. Guilhot, T. Legigan, J. Clarhaut, 2012, Journal of medicinal chemistry.